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RESEARCH ARTICLE
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Abstract
Purpose
Chemotherapy-induced cognitive impairment (CICI) is a common sequelae of cancer thera-
py. Recent preclinical observations have suggested that CICI can be mediated by chemo-
therapy-induced plasma protein oxidation, which triggers TNF-αmediated CNS damage.
This study evaluated sodium-2-mercaptoethane sulfonate (Mesna) co-administration with
doxorubicin to reduce doxorubicin-induced plasma protein oxidation and resultant cascade
of TNF-α, soluble TNF receptor levels and related cytokines.
Methods
Thirty-two evaluable patients were randomized using a crossover design to receive mesna
or saline in either the first or second cycle of doxorubicin in the context of a standard chemo-
therapy regimen for either non-Hodgkin lymphoma or breast cancer. Mesna (360 mg/m2) or
saline administration occurred 15 minutes prior and three hours post doxorubicin. Pre-treat-
ment and post-treatment measurements of oxidative stress, TNF-α and related cytokines
were evaluated during the two experimental cycles of chemotherapy.
Results
Co-administration of mesna with chemotherapy reduced post-treatment levels of TNF-relat-
ed cytokines and TNF-receptor 1 (TNFR1) and TNF-receptor 2 (TNFR2) (p = 0.05 and p =
0.002, respectively). Patients with the highest pre-treatment levels of each cytokine and its
receptors were the most likely to benefit from mesna co-administration.
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Conclusions
The extracellular anti-oxidant mesna, when co-administered during a single cycle of doxoru-
bicin, reduced levels of TNF-α and its receptors after that cycle of therapy, demonstrating
for the first time a clinical interaction between mesna and doxorubicin, drugs often coinci-
dentally co-administered in multi-agent regimens. These findings support further investiga-
tion to determine whether rationally-timed mesna co-administration with redox active
chemotherapy may prevent or reduce the cascade of events that lead to CICI.
Trial Registration
clinicaltrials.gov NCT01205503.
Introduction
Symptoms of chemotherapy-induced cognitive impairment (CICI), or ‘chemobrain’, are com-
mon complaints of cancer survivors. While incidence estimates of CICI vary widely [1], CICI is
recognized as a significant morbidity by the National Cancer Institute and patient advocacy
groups, and therefore is a high priority in survivorship research. There is a lack of consensus re-
garding the causality of CICI [2], and this lack of mechanistic understanding has hampered ef-
forts to prevent CICI. Our working model proposes that oxidative stress and increased
systemic inflammatory cytokines leads to CNS damage and subsequent CICI symptoms in can-
cer survivors. Our group has proposed a mechanism for CICI, in which a TNF-α-mediated
process is initiated by the direct intravascular oxidative modification of plasma proteins by che-
motherapy, followed by monocyte release of TNF-α, with tissue damage then resulting as a
downstream effect of TNF-α [3]. This systemic TNF-α crosses the blood-brain barrier, acti-
vates latent microglia producing yet more TNF-α within the brain, and promulgates a cascade
of events that results in cognitive symptoms. Evidence to support this model includes our prior
demonstration that systemic Doxorubicin (Dox) administration in mice results in increased
brain oxidative stress, even though neither Dox nor its major metabolite has the ability to cross
the blood brain barrier and enter the CNS [4]; that anti-TNF-α antibody prevents the Dox-me-
diated CNS injury in animal models, demonstrating that systemic TNF-α plays a role in Dox-
mediated brain injury [5]; that brain mitochondrial respiration decreases after TNF-αmediat-
ed nitric oxide induction, demonstrating that TNF-α can directly cause the same type of CNS
injury that is observed after Dox administration [6]; and that TNF-α activates brain microglia
to produce even more TNF-α in the microenvironment, demonstrating how TNF-α can stimu-
late a positive feedback loop to amplify the damage initiated by Dox [7].
Therefore, preventing chemotherapy-induced plasma protein oxidation without hindering
tumor intracellular oxidative stress may prevent the initiation of this cascade and thereby pre-
vent CICI without reducing the efficacy of the chemotherapy. In contrast to other antioxidants,
such as N-acetyl-cysteine, sodium-2-mercaptoethane sulfonate (mesna) is a drug that was spe-
cifically found to have poor cellular uptake by most cell types [8]. This specificity allows mesna
to act as an antioxidant only in blood and urine, without interfering with the anticancer activity
of antineoplastic chemotherapy. To support the potential of mesna to block our proposed
mechanism of CICI, we have shown that mesna co-administration blocks Dox-mediated plas-
ma APOA1 oxidation and reduces TNF-α generation in a macrophage cell line [3]; that mesna
directly interferes with Dox-mediated DCF fluorescence, demonstrating mesna-mediating
Mesna, Doxorubicin and TNF-α
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scavenging of Dox-mediated ROS [3], and that in vivomesna co-administration with Dox pre-
vents Dox-induced plasma oxidative stress in mice [9].
We hypothesized that rationally-timed administration of mesna with Dox-containing che-
motherapy could reduce patient plasma protein oxidation and plasma inflammatory cytokine
levels as compared to patients receiving Dox-containing chemotherapy alone. Consequently,
we conducted a pilot study in which cancer patients undergoing therapy with regimens that in-
cluded Dox received their first two prescribed doses of Dox with or without mesna in a ran-
domized order, and then went on to receive the remainder of therapy in a standard fashion.
The primary outcomes were measures of plasma TNF-α, TNF plasma receptor levels which
typically increase in response to TNF-α signaling, IL-18 a downstream messenger of TNF-α
and inflammatory signaling, and plasma protein oxidation.
Methods
Objectives
The primary objective was to determine if co-treatment with mesna significantly reduces plas-
ma protein oxidation and plasma TNF-α levels in patients receiving Dox-containing chemo-
therapy. The secondary objective was to determine if mesna prevented biochemical evidence of
cardiac myocyte injury after Dox administration. The University of Kentucky’s Medical Insti-
tutional Review Board reviewed and approved this clinical study prior to engaging any partici-
pants and all participants were enrolled from the University of Kentucky’s Markey Cancer
Center. This study was listed with clinicaltrials.gov (NCT01205503). All involved participants
provided written informed consent.
Patients
Eligible participants were required to have histologically or cytologically confirmed breast can-
cer or non-Hodgkin lymphoma that required one of the following treatment regimens as their
standard of care treatment: Dox 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC); Dox
50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2 (TAC); or Dox 50 mg/m2,
cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 (capped at 2 mg dose) and prednisone
100 mg +/- rituximab 375 mg/m2 (CHOP+/-R). Additional inclusion criteria included age
>18 years with normal hematopoietic, hepatic and renal functions. A projected sample size of
32 evaluable participants was planned with enrollment of up to an additional eight participants
in the event of nonevaluable participants. Modeling from protein-bound 4-hydroxyenol reduc-
tions with mesna co-administration as compared to Dox alone in a previous observational
study [3], 32 evaluable subjects afford 80% power at α = 0.05 supposing that the observed
mesna effect is 50% of what was observed in the previous study. A total of 33 participants were
enrolled and 32 were eligible for analysis (Fig 1).
Study Design
The study design is shown in Fig 2. Each participant received one cycle of Dox with mesna 15
minutes prior to administration and three hours post administration, and another cycle with
saline instead of mesna. Mesna was administered twice because of mesna’s short plasma half-
life of 1.17 hours [10] to optimize the protective effect throughout Dox’s multiphasic plasma
clearance during which 90% or greater of doxorubicin and metabolites are cleared within six
hours of administration [11]. Patients were randomized in a crossover design to receive mesna
versus saline on the first or second cycle because it was not known if the order would affect the
outcome variables. Stratified block randomization with stratification for tumor type between
Mesna, Doxorubicin and TNF-α
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lymphoma and breast cancer was used with an 1:1 allocation ratio. The sequential randomiza-
tion scheme was determined by the study statistician based off a SAS macro for blocked ran-
domization with varying block sizes of 4 and 6 [12] and all other investigators where blinded to
which cycles contained mesna and which contained saline. Upon enrollment, each new partici-
pant was given a participant number. Only the pertinent pharmacist and statistician had access
Fig 1. Flow of patient enrollment.
doi:10.1371/journal.pone.0124988.g001
Fig 2. Study design.
doi:10.1371/journal.pone.0124988.g002
Mesna, Doxorubicin and TNF-α
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to the randomization key. All participants were followed clinically during these cycles of thera-
py and adverse events were assessed and classified using the Common Terminology Criteria
for Adverse Events version 4. During the experimental cycles, blinded mesna (360 mg/m2) or
saline was infused over 15 minutes, then Dox infused over 15 minutes and then a repeat dose
of assigned mesna or saline was given three hours after the Dox began. To isolate the treatment
effect of mesna co-administration with Dox, the remainder of the chemotherapy regimen was
held until the six-hour post treatment serum samples were collected for analyses and then the
remainder of the prescribed regimen was infused as per standard practice. After these two ex-
perimental cycles, all participants received the remainder of their clinically indicated chemo-
therapy off study as per standard of care.
Statistical Analysis
Descriptive statistics were calculated to summarize each of the cytokine and biochemical mea-
sures at each time point of follow-up for each treatment group. Baseline characteristics were
compared between groups using Fisher’s exact tests or two-sample t-tests where appropriate.
Normality assumptions were checked using qqplots and all measures were log transformed to
better fit with parametric modeling; thus all summary statistics are presented with geometric
means and 95% confidence intervals for the back transformed data (S1 Table) [13]. All cross-
over analyses were conducted in SAS 9.3 using proc mixed. However, there were significant
carry-over effects for the majority of measures. Based on the cross-over model results, a repeat-
ed measures model was performed using the three time points prior to the crossover [14]. All
initial models were adjusted for baseline biochemical measure levels, time of measurement,
treatment received (mesna or saline), treatment type (AC, TAC, CHOP) as the study design
was stratified randomized on this criteria and corresponding first-order interactions. Best
models were selected using backward selection and AIC criterion. All analyses presented were
intent to treat. Additional analyses included calculation of Spearman Correlation coefficients
between baseline biochemical measures and descriptive summaries of adverse event data.
Plasma Samples
During cycles one and two of each participant’s planned treatment, blood samples were ob-
tained immediately prior to test-article administration and six hours after the infusion of Dox.
The blood samples were placed on ice at the bedside and the plasma was prepared within 30
minutes of being drawn to ensure as little modification of plasma proteins as possible. Once
the plasma samples were prepared, they were snap frozen and stored at -80°C until analyses.
Methods for laboratory studies
Oxidative Stress Assays: The slot-blot method was used to determine levels of protein oxidation
[indexed by protein carbonyl (PC) and 3-nitrotyrosine (3-NT)] and lipid peroxidation [in-
dexed by protein-bound 4-hydroxy-2-nonenal (HNE) as previously described [3, 9].
Enzyme-linked Immunosorbent assay (ELISA): Plasma samples were used to measure TNF,
TNFR1, TNFR2 and IL-18 levels, according to the human ELISA following the manufacturer’s
instructions (R&D Systems, Minneapolis, MN). The TNF, TNFR1, TNFR2 and IL-18 concentra-
tion in the sample was calculated from the recombinant human TNF and its receptors as well as
IL-18 standard curves. The means of minimum detectable dose of the assays were 0.106 pg/ml,
0.77 pg/ml, 0.6 pg/ml and 12.5 pg/ml for TNF-α, TNFR1, TNFR2, and IL-18, respectively.
Mesna, Doxorubicin and TNF-α
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Results
Patient Characteristics
Demographics and clinical characteristics of the 32 patients enrolled in the study are summa-
rized in Table 1. The first cycles commenced between October 2010 and May 2012. Patients
were predominantly female (59%), Caucasian (84%) and were on average 55 years old. Of
those enrolled, 59% were diagnosed with lymphoma and the remaining 41% had breast cancer.
Randomization was considered successful, as there were no significant differences between
groups randomized to receive mesna in the first or second cycle regarding gender, race, diagno-
sis, treatment type and ECOG performance status as well as any of the baseline biomarkers or
plasma protein oxidation levels.
Table 1. Demographics for randomized subjects N = 32.
Overall (N = 32) Mesna: Saline
(N = 16)
Saline: Mesna
(N = 16)
p-value*
N % N % N %
Gender 0.15
Female 19 59.38 7 43.75 12 75.00
Male 13 40.63 9 56.25 4 25.00
Race 1.00
White 27 84.30 13 81.25 14 87.50
Black/African American 5 15.63 3 18.75 2 12.50
Ethnicity NA
Non-Hispanic 32 100.00 16 100.00 16 100.00
Treatment Type
AC 11 34.38 5 31.25 6 37.50 1.00
CHOP 19 59.38 10 62.50 9 56.25
TAC 2 6.25 1 6.25 1 6.25
ECOG Performance Status 0.72
0—Fully Active 18 56.25 8 50.00 10 62.50
1—Restricted 14 43.75 8 50.00 6 37.50
Cancer Diagnosis 1.00
Breast 13 40.63 6 37.50 7 21.88
Lymphoma 19 59.38 10 62.50 9 56.25
Age (Mean, Std Dev) 54.78 13.86 51.75 15.51 57.81 11.70 0.22
BSA (Mean, Std Dev) 1.97 0.25 1.93 0.26 2.01 0.23 0.35
Baseline Measures (Mean, Std Dev)
Log TNF ALPHA 1.28 1.12 1.30 1.16 1.27 1.11 0.93
Log TNF Receptor 1 7.17 0.46 7.04 0.46 7.29 0.44 0.13
Log TNF Receptor 2 8.23 0.71 8.15 0.74 8.31 0.68 0.51
Log IL-18 6.11 0.84 6.16 0.76 6.06 0.93 0.74
Log PC 4.36 0.36 4.33 0.38 4.39 0.34 0.65
Log Plasma HNE -0.29 0.21 -0.28 0.20 -0.31 0.22 0.69
Log 3NT -0.08 0.21 -0.05 0.16 -0.11 0.26 0.41
* p-values calculated using Fisher's exact tests for binary or categorical variables and two-sample t-tests for continuous outcomes
doi:10.1371/journal.pone.0124988.t001
Mesna, Doxorubicin and TNF-α
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Biomarker evaluation
The co-administration of mesna with Dox reduced plasma levels of TNF-α, TNFR1 and
TNFR2 compared to saline for patients with high baseline values receiving Dox for breast can-
cer and NHL. There were significant baseline differences between lymphoma versus breast can-
cer patients for TNF-α, TNFR1, TNFR2 and IL-18. To control for these differences, a linear
mixed model found statistically significant differences in these measures over time as well as a
baseline-by-treatment interactions. The baseline value was a significant covariate in these mod-
els (S2 Table). Furthermore, there was a significant interaction between baseline levels and
treatment group indicating that biomarker outcome differences between mesna versus saline
groups differed according to baseline levels of TNF-α.
To further analyze the baseline by treatment interaction, Bonferonni adjustments for post-
hoc comparisons at various baseline levels were considered significant for any p<0.017. As
shown in Fig 3, for patients with the 75% percentile level of baseline values or higher, mesna
Fig 3. Mean estimates of TNF-α levels for each time point by mesna and saline groups calculated from linear mixedmodel adjusting for baseline
level, time, group (mesna vs saline), chemotherapy regimen and baseline by group interaction.
doi:10.1371/journal.pone.0124988.g003
Mesna, Doxorubicin and TNF-α
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decreased TNF-α levels over time relative to the saline group although not statistically signifi-
cant (p = 0.028). Similarly, there was a significant reduction in both TNFR1 (Fig 4) and TNFR2
(Fig 5) for the mesna group compared to saline (p = 0.014 and p = 0.003 respectively) in the
high baseline cohort. There was also a trend of lower average IL-18 levels for the mesna group
compared to saline, although not statistically significant (p = 0.09).
In addition, Table 2 shows that there were significantly positive correlations across TNF-α,
TNFR1, TNFR2 and IL-18 (p< 0.0001), suggesting there is a distinct cytokine signature in-
volving activation of the TNF-α signaling pathway. Furthermore, there were also significant
correlations over time for the repeated measurements of each of the biochemical measures (S3
Table).
Fig 4. Mean estimates of TNF receptor 1 levels for each time point bymesna and saline groups calculated from linear mixedmodel adjusting for
baseline level, time, group (mesna vs saline), chemotherapy regimen and baseline by group interaction.
doi:10.1371/journal.pone.0124988.g004
Mesna, Doxorubicin and TNF-α
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Plasma protein oxidation or lipid peroxidation
Unlike the findings with cytokine levels, there were no significant baseline differences between
lymphoma versus breast cancer patients with PC (77.84 vs. 79.23, p = 0.89), plasma protein-
bound HNE (0.71 vs. 0.80, p = 0.13) and 3-NT (0.93 vs. 0.91, p = 0.79). With regards to PC,
protein-bound HNE, and 3-NT, no statistically significant differences were observed between
the mesna and saline groups at six hours post Dox administration, though a non-statistically
significant reduction in PC was observed with mesna (p = 0.20).
Toxicities
Grade 3 and 4 toxicities are reported in Table 3 and all toxicities regardless of attribution are
listed in S4 Table): Toxicities were summarized for each patient by cycle and the treatment re-
ceived. There were no differences in troponin levels at 6 hours post treatment between the
mesna-containing cycles and the saline-containing cycles. Since the mesna vs saline
Fig 5. Mean estimates of TNF receptor 2 levels for each time point bymesna and saline groups calculated from linear mixedmodel adjusting for
baseline level, time, group (mesna vs saline), chemotherapy regimen and baseline by group interaction.
doi:10.1371/journal.pone.0124988.g005
Mesna, Doxorubicin and TNF-α
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randomization occurred only in the first 2 cycles of therapy, the only cycle that could have ben
delayed by mesna was cycle 2 of the patients randomized to mesna in cycle 1, and there were
no treatment delays for toxicity among these patients.
Discussion
This study has demonstrated that mesna co-administration decreases TNF-α, TNFR1 and
TNFR2 levels after Dox-containing chemotherapy as compared to receiving Dox-containing
Table 2. Spearman Correlations between Baseline Measures.
Correlation (p-
value)
Log TNF
ALPHA Pre1
Log TNF
Receptor 1 Pre1
Log TNF
Receptor 2 Pre1
Log IL-18
Pre1
Log PC Naïve
Baseline
Log Plasma HNE
Naïve Baseline
Log 3NT Naïve
Baseline
Log TNF ALPHA
Pre1
1.00 0.71041 0.82918 0.76613 0.02163 -0.11107 -0.18585
(<.0001) (<.0001) (<.0001) (0.9065) (0.5451) (0.3085)
Log TNF Receptor 1
Pre1
1.00 0.89076 0.74304 0.01576 -0.05865 -0.05095
(<.0001) (<.0001) (0.9318) (0.7498) (0.7818)
Log TNF Receptor 2
Pre1
1.00 0.72654 -0.04069 -0.13563 -0.10777
(<.0001) (0.8250) (0.4592) (0.5571)
Log IL-18 Pre1 1.00 0.07845 -0.06488 -0.12097
(0.6696) (0.7242) (0.5096)
Log PC Naïve
Baseline
1.00 0.24853 -0.33028
(0.1702) (0.0649)
Log Plasma HNE
Naïve Baseline
1.00 -0.33138
(0.0639)
Log 3NT Naïve
Baseline
1.00
doi:10.1371/journal.pone.0124988.t002
Table 3. All grade 3 or 4 toxicities split by treatment and cycle.
Mesna Saline
Cycle 1 (N = 16) Cycle 2 (N = 16) Cycle 1 (N = 16) Cycle 2 (N = 16)
N % N % N % N %
Anemia 0 0% 1 6% 1 6% 1 6%
Blood bilirubin increased 0 0% 0 0% 0 0% 1 6%
Fatigue 0 0% 0 0% 0 0% 1 6%
Febrile neutropenia 0 0% 0 0% 1 6% 1 6%
Headache 2 13% 0 0% 0 0% 0 0%
Hyperglycemia 0 0% 0 0% 1 6% 0 0%
Hypokalemia 0 0% 1 6% 0 0% 0 0%
Hyponatremia 0 0% 0 0% 2 13% 0 0%
Infected Toe 0 0% 0 0% 0 0% 1 6%
Lymphocyte count decreased 2 13% 0 0% 0 0% 3 19%
Nausea 1 6% 0 0% 1 6% 0 0%
Neutrophil count decreased 4 25% 0 0% 5 31% 2 13%
Platelet count decreased 1 6% 0 0% 0 0% 0 0%
Vomiting 0 0% 0 0% 1 6% 0 0%
Weight loss 0 0% 1 6% 0 0% 0 0%
White blood cell decreased 3 19% 2 13% 3 19% 1 6%
Lung infection 0 0% 0 0% 0 0% 1 6%
Total 13 5 15 12
doi:10.1371/journal.pone.0124988.t003
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PLOSONE | DOI:10.1371/journal.pone.0124988 April 24, 2015 10 / 14
chemotherapy alone, indicating a potential role for mesna in mediating toxicities resulting
from TNF-α signaling during cancer treatment. Furthermore, the finding that this effect is
most pronounced in patients with higher baseline levels of TNF pathway-related cytokines sug-
gests that these baseline levels may be biomarkers that can identify patients most likely to bene-
fit from the strategy of rationally administering mesna to patients receiving redox
active chemotherapy.
We embarked on the preclinical and clinical evaluation of mesna interaction with Dox in re-
lationship to TNF-α in part because of our initial findings that patients who were receiving che-
motherapy who coincidentally received mesna with their chemotherapy had significantly less
PC, a marker of oxidative stress (p<0.05) [3]. However, measures of oxidative stress (PC, pro-
tein-bound HNE, 3-NT) in this study did not demonstrate a significant reduction with mesna
co-administration. One reason for the inability to detect differences in plasma protein oxida-
tion or lipid peroxidation may have been the relatively late time point examined, six hours
after Dox administration. It is possible that damaged proteins are rapidly cleared from the cir-
culation and future studies should examine plasma samples obtained closer to the administra-
tion of Dox.
In a previous observational clinical study, paired samples from patients receiving Dox
found that TNF-α plasma levels are significantly increased at six hours after treatment with
Dox [3]. This clinical finding is consistent with our preclinical murine findings that Dox ad-
ministration causes an increase in plasma TNF-αmeasured six hours after Dox administration
while concomitant treatment with mesna reduces this increase in TNF-α [3]. However, in this
current study, mean plasma TNF-α decreased by six-hours post administration of Dox-con-
taining chemotherapy with or without mesna, though participants with higher baseline levels
of TNF-α did have a significantly greater reduction at six hours than when receiving concomi-
tant mesna. Interestingly, subjects in this current trial enrolled with elevated pre-treatment
plasma TNF-α levels in comparison to levels seen in healthy volunteers [15]. It is possible that
pre-treatment TNF-α level is related to tumor burden and that early treatment effect may
begin to reduce this TNF-α input shortly upon treatment, which may explain the decline of
TNF-α levels in the saline group with the highest baseline values. However, in this study, the
inclusion of patients with both lymphoma and breast cancer confounded any determination of
the relation of tumor burden to cytokine levels. Future clinical studies may be strengthened by
stratification by tumor burden, and preclinical studies using tumor-bearing mice are planned.
Mesna is approved by the U.S. FDA for the prevention of hemorrhagic cystitis after treat-
ment with ifosfamide chemotherapy. Upon intravenous infusion, mesna is rapidly oxidized to
mesna disulfide (dimesna). Mesna and dimesna are rapidly filtered and excreted by the kid-
neys. In the nephron dimesna is reduced back to mesna and in the bladder mesna detoxifies
acrolein and other toxic ifosfamide metabolites. Mesna is rapidly filtered by the kidneys and
has a very limited volume of distribution [16]. Mesna is not thought to interfere with che-
motherapy’s therapeutic efficacy [17] and is routinely coincidentally administered with multi-
agent chemotherapy regimens without clinical concern.
In our pre-clinical murine studies, Dox administration resulted in increased brain oxidative
stress, even though neither Dox nor its major metabolite cross the blood brain barrier and
enter the CNS [4], suggesting that chemotherapy- induced CNS events occur not due to direct
toxicity from chemotherapy but via a secondary messenger or downstream event. Similar mu-
rine studies conducted with systemic co-administration of TNF-α neutralizing antibodies with
chemotherapy found that inhibiting systemic TNF-α prevented the CNS injury associated with
systemic chemotherapy administration [5]. Building upon the earlier finding that plasma
ApoA1 participates in TNF-α suppression [18], we found that oxidation of plasma ApoA1 im-
paired its ability to suppress TNF-α secretion by monocytes, and that mesna co-incubation
Mesna, Doxorubicin and TNF-α
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with Dox protected ApoA1 from oxidation and prevented Dox-mediated TNF-α secretion
from a macrophage cell line [3].
In the current study, the amount of inflammatory cytokine reduction achieved by co-ad-
ministration of mesna with chemotherapy positively correlates with the patient’s pre-treatment
cytokine levels. As illustrated in Figs 3–5, patients who presented with the lowest quartiles sys-
temic TNF-α TNFR1 and TNFR2 may receive little benefit in terms of cytokine signals with
the co-administration of mesna, while those who present with levels at the highest quartile
have the largest percent reduction in inflammatory cytokines with mesna co-administration. In
recent studies of breast cancer survivors, key polymorphisms in TNF-related signaling path-
ways correlate with the severity of neurocognitive sequelae [19]. Taken together, these findings
reinforce the relevance of the TNF-α pathway and naturally lead to the question of whether cy-
tokine level or related polymorphisms may predict those most at risk to develop CICI and
serve as a marker of who may benefit the most from mesna co-administration.
Our study has important limitations. First, though the rationale of the study was based on
our preclinical data that link Dox-mediated plasma protein oxidation, TNF-α and cognitive
dysfunction, we did not measure any cognitive outcomes in the patients enrolled in the study.
Our rationale was that we first wanted to demonstrate that mesna had the postulated biochemi-
cal effect on plasma protein oxidation and inflammatory cytokines before exposing a cohort of
patients to rationally administered mesna during all cycles of therapy. Also, we did not measure
the levels of anti-inflammatory cytokines, which also could play a role in our model of patho-
physiology of CICI.
In summary, we have shown that co-administration of mesna during one cycle of Dox-
based chemotherapy reduced the post-treatment levels of TNF-α, TNFR1 and TNFR2. Subset
analyses further support the additional hypothesis that those patients who present with highest
pre-treatment levels of TNF-α, TNFR1 and TNFR2 are the most likely to benefit from mesna
co-administration and should be prospectively tested in future studies. Although this study did
not directly address the potential clinical role for mesna in the prevention of CICI, it did dem-
onstrate a clinical interaction between mesna and Dox on cytokine levels associated with CICI,
and therefore provides a clinical basis for a future mechanistically-based prospective evaluation
of mesna for the prevention of CICI.
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